News | December 04, 2025
Briefs: Sun Pharma and Venus Remedies
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Subscribe To Our Newsletter & Stay Updated
